ImmunityBio, Inc.

As of June 30, 2026, ImmunityBio Inc carries a market capitalization of 8.03B, placing it among publicly traded companies globally. Its enterprise value stands at 8.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ImmunityBio Inc's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, ImmunityBio Inc has 1.05B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 52.68, and the price-to-book ratio stands at -8.76.

These figures are as of June 30, 2026. The EV/Sales ratio of 58.06 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 8.43B versus a market cap of 8.03B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ImmunityBio Inc maintains a current ratio of 5.72, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -77.75, indicating conservative leverage, while an interest coverage ratio of -2.05 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -192.58, reflecting losses generated across the asset base. The company generates approximately 210,850.33 in revenue per employee across its workforce of 688.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.26 indicates how many times ImmunityBio Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ImmunityBio Inc recorded an income tax benefit of -140,923.30 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -868.81M and -868.61M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, ImmunityBio Inc's stock has gained approximately 282.74% over the past 52 weeks. The 50-day moving average sits at 7.50, while the 200-day moving average is 6.73.

Over the twelve months ended June 30, 2026, ImmunityBio Inc generated 145.12M in revenue and converted that into -868.61M in net income, yielding earnings per share of -0.87. EBITDA reached -205.87M, while operating income came in at -220.40M.

As of June 30, 2026, ImmunityBio Inc holds 312.81M in cash and equivalents against 711.67M in total debt, resulting in a net debt position of 611.55M. Total book value stands at -916.11M, with working capital of 317.08M providing operational flexibility.

ImmunityBio Inc produced -246.08M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -6.46M in capital expenditures, free cash flow totaled -252.54M - equivalent to -0.25 per share.

Over the twelve months ended June 30, 2026, ImmunityBio Inc posted a gross margin of 99.34, reflecting its pricing power and cost economics. The operating margin of -151.88 and net profit margin of -598.56 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.30: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.42, meaning ImmunityBio Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, ImmunityBio Inc has an Altman Z-Score of -7.51, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.